These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 32331305)
21. Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse. Hansen TM; Sabourin BC; Oketola B; Bernstein CN; Singh H; Targownik LE Inflamm Bowel Dis; 2020 Aug; 26(9):1401-1406. PubMed ID: 31725152 [TBL] [Abstract][Full Text] [Related]
22. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. ; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505 [TBL] [Abstract][Full Text] [Related]
23. Advances in inflammatory bowel diseases in children. Michail S; Ramsy M; Soliman E Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319 [TBL] [Abstract][Full Text] [Related]
24. [Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review]. Volz MS; Siegmund B; Häuser W Schmerz; 2016 Feb; 30(1):37-46. PubMed ID: 26809974 [TBL] [Abstract][Full Text] [Related]
25. Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial. Naftali T; Bar-Lev Schleider L; Almog S; Meiri D; Konikoff FM J Crohns Colitis; 2021 Nov; 15(11):1799-1806. PubMed ID: 33858011 [TBL] [Abstract][Full Text] [Related]
26. The impact of mangiferin from Belamcanda chinensis on experimental colitis in rats. Szandruk M; Merwid-Ląd A; Szeląg A Inflammopharmacology; 2018 Apr; 26(2):571-581. PubMed ID: 28337639 [TBL] [Abstract][Full Text] [Related]
27. Attitudes towards and use of cannabis in New Zealand patients with inflammatory bowel disease: an exploratory study. Appleton K; Whittaker E; Cohen Z; Rhodes HM; Dunn C; Murphy S; Gaastra M; Galletly A; Dougherty S; Haren A; Sukumaran N; Aluzaite K; Dockerty JD; Turner RM; Schultz M N Z Med J; 2021 Feb; 134(1530):38-47. PubMed ID: 33651776 [TBL] [Abstract][Full Text] [Related]
28. Cannabis finds its way into treatment of Crohn's disease. Schicho R; Storr M Pharmacology; 2014; 93(1-2):1-3. PubMed ID: 24356243 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Laverny G; Penna G; Vetrano S; Correale C; Nebuloni M; Danese S; Adorini L Immunol Lett; 2010 Jun; 131(1):49-58. PubMed ID: 20350569 [TBL] [Abstract][Full Text] [Related]
30. Inflammatory bowel disease: new therapies from antisense oligonucleotides. Marafini I; Monteleone G Ann Med; 2018 Aug; 50(5):361-370. PubMed ID: 29911450 [TBL] [Abstract][Full Text] [Related]
31. Roles of protein ubiquitination in inflammatory bowel disease. Xiao Y; Huang Q; Wu Z; Chen W Immunobiology; 2020 Nov; 225(6):152026. PubMed ID: 33190004 [TBL] [Abstract][Full Text] [Related]
32. A review of current evidence allied to step-up and top-down medication therapy in inflammatory bowel disease. Salahudeen MS Drugs Today (Barc); 2019 Jun; 55(6):385-405. PubMed ID: 31250843 [TBL] [Abstract][Full Text] [Related]
33. Current scenario in inflammatory bowel disease: drug development prospects. Chandel S; Prakash A; Medhi B Pharmacol Rep; 2015 Apr; 67(2):224-9. PubMed ID: 25712643 [TBL] [Abstract][Full Text] [Related]
34. Inflammatory pathways of importance for management of inflammatory bowel disease. Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859 [TBL] [Abstract][Full Text] [Related]
35. Medical marijuana for inflammatory bowel disease: the highs and lows. Wynne J; Kozuch P Scand J Gastroenterol; 2022 Feb; 57(2):197-205. PubMed ID: 34919496 [TBL] [Abstract][Full Text] [Related]
36. Curcumin as a therapeutic agent in the chemoprevention of inflammatory bowel disease. Sreedhar R; Arumugam S; Thandavarayan RA; Karuppagounder V; Watanabe K Drug Discov Today; 2016 May; 21(5):843-9. PubMed ID: 26995272 [TBL] [Abstract][Full Text] [Related]
37. Pharmacological Autophagy Regulators as Therapeutic Agents for Inflammatory Bowel Diseases. Retnakumar SV; Muller S Trends Mol Med; 2019 Jun; 25(6):516-537. PubMed ID: 30952481 [TBL] [Abstract][Full Text] [Related]
38. [The use of methotrexate in an inflammatory bowel diseases based on the review of the current literature]. Klimczak K; Łykowska-Szuber L; Krela-Kaźmierczak I; Eder P; Szymczak A; Stawczyk-Eder K; Linke K Wiad Lek; 2016; 69(2 Pt 2):262-6. PubMed ID: 27487545 [TBL] [Abstract][Full Text] [Related]
39. Current pharmacotherapy for inflammatory bowel disease. McKaig BC; Stack WA Expert Opin Pharmacother; 1999 Nov; 1(1):3-14. PubMed ID: 11249561 [TBL] [Abstract][Full Text] [Related]
40. Curcuminoids from Cunha Neto F; Marton LT; de Marqui SV; Lima TA; Barbalho SM Crit Rev Food Sci Nutr; 2019; 59(13):2136-2143. PubMed ID: 29565637 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]